A visible effect of hexacosanol on the autophagy induction mediated by the upregulation of autophagy-related genes (ATG16L) and anti-microtubule-associated protein 1A/1B light chain 3 (LC3-II) has been documented to aid in mitigating hepatic lipid accumulation and, consequently, fatty liver changes [44], supporting the present outcomes concerning the inhibition of fatty liver changes in response to Raydel® policosanol. Here, ATG16L1 is linked to fatty liver disease.